Research Results

 
The following research article abstract is provided with the permission of the publisher. Please print this page and share it with your doctor.

Potassium Paraaminobenzoate (Potaba trademark) in the Treatment of Peyronie's Disease: A Prospective, Placebo-Controlled, Randomized Study.

European Urology 2005 Apr; 47(4) 530-536.

Weidner W; Hauck EW; Schnitker J.

Department of Urology and Pediatric Urology

The Peyronie's Disease Study Group of the Andrological Group of German Urologists.

PURPOSE:  The aim of this study was to investigate the effect of potassium paraaminobenzoate (Potaba trademark) in Peyronie's Disease in a prospective, randomized, double-blind, placebo-controlled, multicentre study during a 12-months period of treatment.

PATIENTS AND METHODS:  103 patients with Peyronie's Disease and a history < 12 months, non-calcified plaques, and without pre-treatment were included.  51 were randomized to potassium paraaminobenzoate, 52 to placebo receiving 4 x 3 grams/day for 12 months.   Follow-up was performed during the treatment period.  Response has been defined as regression in plaque-size and/or reduction in penile curvature of at least 30%.  Data analysis was focused on 75 patients who completed the study [valid-cases(VC)].

RESULTS:  No severe adverse events occurred.  Response rates were 74.3% on potassium paraaminobenzoate and 50.0% on placebo (p=0.016).  Mean plaque-size decreased from 259 mm(2) to 142 mm(2) in the treatment arm.  In the placebo group, plaque-size aggravated from 259 mm(2) to 303 mm(2) after 6 months but improved slightly to 233 mm(2) after 12 months.  Differences between the groups were significant (p=0.042).   Pre-existing curvature did not improve under the drug (p=0.066) but comparing the development of new curvature or deterioration of pre-existing curvature under potassium paraaminobenzoate, penile deviation remained stable.  However, under placebo penile curvature deteriorated significantly in 32.5% of the cases (p<0.001).  No significant differences concerning decrease of pain could be observed between the two groups (82.6% vs. 77.3%).

CONCLUSIONS:  The results of this study indicate a significant plaque-related effect of potassium paraaminobenzoate.  There was no relevant difference with regard to improvement of pre-existing penile deviation.  However, under potassium paraaminobenzoate a significant protective effect on deterioration of penile curvature could be demonstrated.  Potassium paraaminobenzoate appears to be useful to stabilize the disorder and prevent progression of penile curvature.

Abstract text ©2005 Elsevier Science, Inc.

Potaba is a trademark of Glenwood, LLC.

Hope Pharmaceuticals' Aminobenzoate Potassium USP Capsules is the generic equivalent for Potaba®  capsules.